Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) just unveiled an announcement.
JW (Cayman) Therapeutics has granted a total of 2.6 million share options and 650,000 restricted share units to four grantees under its post-IPO equity incentive and restricted share unit schemes adopted in 2020, as part of its ongoing remuneration and retention strategy. The bulk of the options, 1.5 million, were awarded to CEO and executive director Feng Tian at an exercise price of HK$2.92 per share, with options and RSUs subject to multi-year vesting schedules; the company’s remuneration committee stated that the time-based vesting for Tian, without additional performance targets, is consistent with its customary equity-based pay practices and aimed at aligning management interests with shareholders over the long term.
The most recent analyst rating on (HK:2126) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a Hong Kong-listed biotechnology company focused on developing and commercializing innovative cell therapies, particularly for cancer treatment, with operations conducted through its subsidiaries in Mainland China and other related markets.
Average Trading Volume: 1,509,783
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.23B
For a thorough assessment of 2126 stock, go to TipRanks’ Stock Analysis page.